Welcome to our dedicated page for Rockwell Med SEC filings (Ticker: RMTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rockwell Medical filings document the company’s hemodialysis-products business, public-company governance, capital-market status, and material-event disclosures. Form 8-K reports cover quarterly and annual operating results, preliminary financial information, corporate presentations furnished under Regulation FD, and product-related business updates incorporated through exhibits.
The company’s proxy materials cover annual meeting matters, director elections, executive compensation, equity awards, and board governance. Other filings disclose common stock registered on the Nasdaq Capital Market, listing-rule compliance notices, and board changes, including director departures, appointments, committee service, and related governance matters.
Rockwell Medical, Inc. (RMTI) filed a Form 144 indicating that 6,926 common shares may be sold under Rule 144. The proposed transaction will be executed through Raymond James & Associates on or after 1 July 2025.
The shares were acquired via RSU vesting on 17 March 2024. At the indicated aggregate market value of $5,536, the filing equates to roughly 0.02 % of the company’s 34.17 million shares outstanding; therefore, the sale is immaterial to share-count dilution and likely has negligible impact on liquidity.
The seller identified in the past-sales table is Mark Strobeck, who disposed of an identical 6,926-share block on 1 April 2025 for gross proceeds of $7,263. The current notice affirms that the filer is not aware of undisclosed material adverse information and is acting in compliance with SEC Rule 144 and related insider-trading provisions.
Overall, the filing represents routine insider portfolio management rather than a signal of fundamental change.